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ABSTRACT
Objectives: To demonstrate that lifestyle
modifications will reduce the cost of routine
medications in individuals with type 2 diabetes (T2D),
through a mechanism involving glycaemic control.
Design: A within-trial cost-medication analysis with a
1-year time horizon.
Setting: Controlled environment within the spa resort
of Chatel-Guyon, France.
Participants: Twenty-nine participants (aged 50–
70 years) with T2D.
Interventions: A 1-year follow-up intervention,
beginning with a 3-week residential programme
combining high exercise volume (15–20 hours/week),
restrictive diet (−500 kcal/day) and education.
Participants continued their routine medication,
independently managed by their general practitioner.
Main outcome measures: Number of medications,
number of pills, cost of medications and health-related
outcomes.
Results: Twenty-six participants completed the 1-year
intervention. At 1 year, 14 patients out of 26 (54%)
stopped/decreased their medications whereas only 5
(19%) increased or introduced new drugs (χ2=6.3,
p=0.02). The number of pills per day decreased by 1.3
±0.3 at 12 months (p<0.001). The annual cost of
medications for T2D were lower at 1 year (€135.1
±43.9) versus baseline (€212.6±35.8) (p=0.03). The
regression coefficients on costs of routine medication
were 0.507 (95% CI 0.056 to 0.959, p=0.027) for
HbA1c and 0.156 (95% CI −0.010 to 0.322, p=0.06)
for blood glucose levels. Diabetics patients with HbA1c
>6.5% in the highest (last) quartile doubled their
routine medication costs (66% vs 33%, p=0.037).
Conclusions: Individuals with T2D reduced routine
medication costs following a long-term lifestyle
intervention that started with a 3-week residential
programme. Combining high exercise volume,
restrictive diet and education effectively supported the
health of T2D. The main factor explaining reduced
medication costs was better glycaemic control,
independent of weight changes. Despite limitations
precluding generalisability, cost-effective results of
reduced medication should contribute to the evidence
base required to promote lifestyle interventions for
individuals with T2D.
Trial registration number: NCT00917917;
Post-results.
BACKGROUND
Type 2 diabetes mellitus (T2D) is a major
health issue that is associated with consider-
able morbidity and mortality.1 Globally, the
number of people with T2D is projected to
increase to 366 million by 2030.2 As many as
one in three US adults could have T2D by
2050, if current trends continue.3
The costly and debilitating microvascular
and macrovascular complications of poorly
controlled diabetes include renal failure,
visual impairment, lower limb amputation,
heart disease and stroke. Therefore, intensive
and sustained individual effort is required to
Strengths and limitations of this study
▪ Reducing the long-term cost of global routine
medication was effective following a lifestyle resi-
dential programme in type 2 diabetes (T2D)
patients.
▪ Innovation also lies in high training volumes
(15–20 hours/week) that have seldom been
investigated in obesity intervention over
12 months.
▪ The main limitations are a small sample size of
T2D patients and the absence of a control group.
▪ A group without physical activity could also have
provided opportunities to distinguish the effects
of physical activity from the diet.
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achieve optimum control.4 T2D imposes a substantial
burden on the economy worldwide in the form of
increased medical costs and indirect costs from work-
related absenteeism, reduced productivity at work and at
home, reduced labour force participation from chronic
disability and premature mortality.5 In 2007, the global
health expenditure to treat and prevent T2D and its
complications was estimated to be at least US$232
billion,6 increasing dramatically in recent years.
Depending on available treatments and local prevalence,
the direct costs of T2D consume from 2.5% to 15.0% of
annual healthcare budgets.7
T2D is a chronic illness requiring continuous medical
care with multifactorial risk reduction strategies beyond
glycaemic control.8 Inadequate glycaemic control is
thought to be a cause of diabetic complications and
higher costs. Appropriate management of diabetes can
delay complications, reduce mortality and reduce the
costs of diabetes care, particularly medical costs.
The latest recommendations from diabetes care in
2015 concluded that education for self-management is
critical.8 Within the recommendations, adults with dia-
betes were advised to perform at least 150 min/week of
moderate-intensity aerobic physical activity (at 50–70% of
maximum heart rate), spread over at least 3 days/week
with no more than 2 consecutive days without exercise. In
the absence of contraindications, it was recommended
that adults with T2D perform resistance training at least
twice per week. Moreover, the integral role of nutrition
therapy was emphasised, including a balance diet asso-
ciated with reduction in excess body weight for overweight
patients. However, although physical activity and nutrition
represent a cornerstone for managing T2D, it is often difﬁ-
cult to incorporate regular physical activity into daily lives,
in combination with healthy nutritional intake. To date,
no study combining physical activity and nutrition has spe-
ciﬁcally investigated T2D medical costs before and after a
3-week residential programme with a long-term follow-up
at 12 months. Moreover, no study has examined the rela-
tion between glycaemic control and medical costs after
lifestyle modiﬁcations.
We hypothesised that (1) lifestyle modiﬁcations would
reduce the costs of routine medications in T2D patients
and (2) the glycaemic control would be a major factor
explaining this reduction.
Therefore, we aimed to evaluate any reductions of
routine medications in T2D patients after a lifestyle
intervention. A secondary aim was to investigate the asso-
ciation between the cost of medications and clinical as
well as biological parameters. This study is part of the
larger REverse metabolic SyndrOme by Lifestyle and
Various Exercises (RESOLVE) trial.
METHODS
Participants
Participants were recruited via advertisements. They pro-
vided written informed consent. Participants were
eligible if they met the following criteria: being aged
between 50 and 70 years, suffering from T2D, practicing
<3 hours of physical activity per week, having a stable
body weight, without changes in prescribed medications
over the previous 6 months, and without hepatic, renal
or psychiatric diseases. Potential participants also
needed to be free from endocrine diseases, except the
insulin-resistance deﬁning T2D, and without medica-
tions known to alter body weight, nor having a history of
restricted dieting in the previous year. Further, partici-
pants needed to complete a maximal exercise tolerance
test that included continuous ECG monitoring, attesting
to the absence of cardiovascular disease. For baseline
comparisons, aged-matched healthy controls were
recruited with no disease/medication and parameter of
the metabolic syndrome,9 as metabolic syndrome is con-
sidered as a pre-diabetic stage.10
First stage of intervention: a 3-week residential
programme
Participants attended lectures and educational workshops
on T2D, nutrition, cooking and exercise including a
strong focus on sustainable lifestyle changes. Throughout
the residential programme, food intake and physical
activity were continuously monitored to reach targets set
by investigators. Nutritional intakes were assessed by dieti-
cians. T2D participants underwent a daily diet restriction
(−500 kcal/day) with protein accounting for 15–20% of
the total energy intake (1.2 g/kg/day), lipids 30–35%
and carbohydrates the remainder. Basal metabolic rate
(BMR) was calculated using the equations of Black.11
Participants were coached individually by physical educa-
tion professionals. Participants had to exercise 15–
20 hours/week, using endurance training (90 min daily:
aquagym, cycling or walking) and resistance training
(90 min × 4 days a week). Resistance training consisted of
eight exercises with free weights and traditional muscle
building equipment. Sundays were dedicated to a whole-
day trek. Heart rate was monitored by Polar S810 allowing
to calculate the energy expenditure.12
Second stage of intervention: a 1-year at-home follow-up
Following the ﬁrst stage of intervention (D20), T2D par-
ticipants continued their lifestyle changes at home for
1 year. They were asked to maintain the lifestyle (diet
and physical activity) changes experienced during the
residential programme. Dietary and exercise practices
during this period were assessed with the use of a com-
pliance score determined on the basis of the number of
food questionnaires returned and the number of train-
ing sessions undertaken per week. The overall compli-
ance score was the mean of these two scores (nutrition
and physical activity)13 (ﬁgure 1).
Primary outcomes: medications
Participants were advised to continue their medication
which was independently managed by their general
practitioner.
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Routine medications and number of pills per day were
recorded. Cost of treatment were calculated on the basis
of the cost given by the dictionary of medications
(Guide thérapeutique, Elsevier-Masson, 2014) for
France, and on online sale of drugs (Rxusa,
Pharmacychecker) for the USA. We multiplied the cost
of one pill by the number of pills per day by 365 days to
calculate the annual cost for each medication.
Secondary outcomes
Central fat, a surrogate of visceral fat, was assessed from
dual-energy X-ray absorptiometry (DXA, Hologic QDR
4500 series; Waltham, USA), according to Kamel et al.14
Our laboratory reports in vivo coefﬁcients of variation
(CV) of 1.6% in central fat measures from 20 partici-
pants. The CV for total body mass was 4.2%. Blood pres-
sure and heart rate were measured after 15 min of rest,
using an automated upper arm sphygmomanometer
(SunTech Medical, Model 222).
Fasting blood samples were drawn between 7:00 and
7:30, aliquoted and stored at −80°C until analyses. Basic
biological assays were performed in the biochemistry
laboratory of the University Hospital (Clermont-Ferrand,
France). Insulin, pro-inﬂammatory cytokines (tumor
necrosis factor (TNF-α) and interleukin 6 (IL-6)), vas-
cular endothelial growth factor (VEGF) and N-terminal
pro-brain natriuretic peptide (NT-proBNP) were
assayed by ELISA kits (Millipore, Billerica,
Massachusetts, USA). Sensitivity, intra-assay and interas-
say CV were, respectively, 3.0 ng/mL, 2.6%, 7.2% for
insulin, 0.7 pg/mL, 6.0% and 9.0%, for TNF-α, 1.3 pg/
mL, 7.0% and 10.0% for IL-6, 5.9 pg/mL, 4.1% and
5.4% for VEGF.
Physical performance tests were conducted for
strength and endurance. Speciﬁcally, strength was
evaluated by summing the maximum load of 10 repeti-
tions from three prescribed exercises (bench press, leg
extension, biceps curl).13 Endurance was assessed by the
6 min walk test (6MWT).15
Time of measures
Data were collected at baseline (day 0), 21 days (D20),
3 months (M3), 6 months (M6) and 12 months (M12).
Statistical analysis
Statistical analyses were performed using SPSS (v19,
SPSS ., Chicago, Illinois, USA) and Stata software (v12,
Stata-Corp, Texas, USA). Data are presented as mean ±
SD unless otherwise speciﬁed. Normality of distribution
was assessed by the Shapiro-Wilk test. The primary
focus of the analyses was the 12-month change in mean
number of pills per day. Results of a previous similar
intervention12 showed that a prediabetic population
decreased their medications’ cost of €75±100 at
6 months. Using medications’ cost as the main outcome
and with the assumption that T2D patients will
undergo similar beneﬁts at 1 year, we calculated that a
sample of 27 participants allows a statistical power
>80% with an α level <5%, correlation coefﬁcient at 0.5
(due to paired context), allowing a dropout rate of
20%. Changes over time were tested by a one-way
ANOVA with repeated measures, with the use of
Bonferroni post hoc test. We further calculated the
global tendency over time (over the 1-year intervention
programme). Correlation matrices between T2D
patients medication cost and various clinical and bio-
logical parameters were constructed using Pearson or
Spearman test, according to statistical distribution. To
minimise the probability of false positives when numer-
ous correlations are calculated, the independent
Figure 1 Study design: a 3-week residential programme with standardised and personalised diet and physical activity, and a
1-year at-home follow-up. 6MWT, 6 min walk test; BP, blood pressure; DXA, densitometry X-ray absorption; HR, heart rate; WC,
waist circumference.
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associations of each parameter with medication cost
were further assessed using a multivariable negative
binomial generalised estimating equations (GEE)
model. Indeed, the GEE approach allowed estimating
the population average parameter; taking into account
the clustering of participants, and applying the latter
aspect in a working correlation matrix in the model.
When the data are overdispersed (eg, for cost of
routine medication), using negative binomial distribu-
tion is an appropriate alternative. We described our
results calculating the regression coefﬁcient and 95%
CI for each dependent variable on medication cost.
Generalised linear mixed models (GLMM) with a log
link function were performed to compare the number
of participants depending on their characteristics and
their routine medication cost. To study the parameters
inﬂuencing the highest routine cost medications, this
outcome was categorised in four modalities based on its
statistical distribution (quartiles) and its clinical rele-
vance. The descriptive characteristics of those who
dropped out of the programme were also summarised.
We also performed a descriptive statistical analysis for
participants who dropped out to compare their
characteristics with those who completed the pro-
gramme. Signiﬁcance was set at the p<0.05 level.
RESULTS
Participants
Twenty-nine participants (13 men, 16 women, aged 59.3
±5.1 years, 93.6±14.1 kg, body mass index 34.5±3.7 kg/
m2) with T2D were recruited into this 1-year study start-
ing with a 3-week residential programme. Three T2D
patients were not taking medication for their diabetes.
Among participants, 83% were taking blood pressure
medications and 66% were taking lipid-lowering drugs
(table 1). Baseline analyses resulted in mean blood
values of 6.6±1.9 mmol/L for glucose and 7.0±0.8% for
HbA1c, as well as 142.4±11.5 mm Hg for systolic and
84.7±8.7 mm Hg for diastolic blood pressure. One par-
ticipant left the study during the 3-week residential pro-
gramme. Eighty-three per cent completed the whole
intervention (ﬁgure 1). Baseline characteristics and car-
diovascular risk proﬁles did not differ between those
Table 1 Profile of routine medication by class and change at 1 year
At 1 year
Baseline (n=29) Stop Decrease Increase
Routine medication—number of patients treated for:
Diabetes 26 4 1 1
Blood pressure 24 4 1 1
Lipid-lowering 19 1 – –
Analgesic 1 – – –
Other 14 3 – 3
ALL 29 12 2 5
Routine medication—number of medication treating for:
Diabetes 36 4 1 1
Biguanides 20 3 1 –
Sulfamides 8 – – –
Incretins 1 – – –
Glitazones 2 1 – –
Glinides 1 – – 1
Others 4 – – –
Insulin (exclusion criteria) – – – –
Blood pressure 42 5 1 3
β-Blockers 4 – – 1
ACE inhibitors 5 – 1 –
Angiotensin II receptor antagonists 13 2 – –
Loop diuretics 1 1 – 1
Thiazidic diuretics 9 – – –
Potassium-sparing diuretics 5 – – 1
Calcium blockers and central agents 5 2 – –
Lipid-lowering 20 1 – –
Statins 13 1 – –
Fibrates 6 – – –
Others 1 – – –
Analgesic 1 – – –
Others 41 7 – 4
ALL 140 17 2 8
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Table 2 One-year follow-up of outcomes in type 2 diabetes patients
Day 0 Day 20 Month 3 Month 6 Month 12
Global tendency
over time
p Value
Weight, cm 91.1±13.5 86.4±12.4*** 85.0±12.1***††† 86.5±13.5*** 87.2±12.9** <0.001
Waist circumference, cm 105.0±10.4 100.0±9.3*** 97.4±8.3***†† 98.5±9.2*** 98.2±9.2*** <0.001
Central fat, g 3250.7±760.4 2813.0±625.6*** 2553.9±595.3***††† 2631.1±807.0***‡ 2776.4±712.3*** <0.001
Mean blood pressure, mm Hg 103.9±8.0 96.3±8.8*** 102.3±6.4††† 104.4±8.7††† 104.7±9.8††† 0.015
Systolic blood pressure, mm Hg 142.4±11.5 133.4±9.7*** 138.8±8.2*†† 140.5±11.7‡ 140.9±12.9§§ 0.431
Diastolic blood pressure, mm Hg 84.7±8.7 77.8±9.5*** 84.1±8.4††† 86.4±8.8‡‡‡ 86.6±10.2§§§ 0.003
Pulse pressure, mm Hg 57.7±11.8 55.6±7.9 54.7±11.2 54.1±9.9 54.3±11.4 0.074
HbA1c, % 7.0±0.8 6.6±0.8*** 6.3±0.7***†† 6.2±0.7***‡‡ 6.4±0.8*** <0.001
Blood glucose levels, mmol/L 6.6±1.9 5.2±1.1*** 5.1±1.1*** 5.4±1.3** 5.4±1.1** 0.002
Insulin, mIU/L 41.1±13.2 34.8±15.1** 44.7±16.6†† 52.4±18.1**‡‡‡ 42.6±16.0§ 0.015
Cholesterol, mmol/L 5.2±1.0 4.3±1.1*** 5.1±1.2††† 5.0±0.6‡‡‡ 5.1±0.7§§§ 0.235
Triglycaerides, mmol/L 2.0±1.1 1.4±0.3*** 1.7±0.9* 1.7±1.0* 1.9±1.3§ 0.554
High-density lipoprotein (HDL), mmol/L 1.2±0.2 1.1±0.2 1.3±0.2**†† 1.3±0.3**‡‡ 1.3±0.3***§§§ <0.001
Low-density lipoprotein (LDL), mmol/L 3.3±1.2 2.5±1.1*** 3.1±1.1††† 3.0±0.9‡‡‡ 3.0±0.7§§ 0.995
Creatine, µmol/L 71.9±20.7 76.0±25.8* 75.1±21.8 73.1±20.6 75.8±19.9 0.300
hs C reactive protein (CRP), mg/L 4.9±4.6 3.3±3.2* 5.4±7.1 3.0±2.2** 2.8±2.5** 0.060
IL-6, pg/mL 4.2±4.5 2.9±2.8 2.6±3.0** 2.3±2.1** 1.9±1.1**§ <0.001
NTproBNP, pg/mL 27.3±73.5 40.0±61.0 41.2±57.8 25.2±51.8 24.8±36.4 0.420
VEGF, pg/mL 247.7±316.8 235.7±298.6 179.7±99.2 173.5±245.5 197.5±258.5 0.217
TNF, pg/mL 11.4±9.3 9.3±4.4 5.1±3.1**††† 5.7±2.4**‡‡‡ 5.9±3.0*§§§ <0.001
Six minutes’ walk test, m 561.7±74.1 612.1±64.1*** 638.3±79.4***†† 644.8±75.9***‡‡ 638.8±60.2***§ <0.001
Strength max, kg 399.3±210.1 464.0±242.5** 584.6±310.1***†† 597.9±300.8***‡‡ 592.8±320.2** <0.001
Routine medications:
Total cost/year, € 1352.6±1764.8 1325.9±1775.9** 1305.3±1785.9** 1307.7±1762.9 1239.5±1660.3 0.135
Routine pills, number 7.6±3.1 6.9±3.4*** 6.6±3.5***† 6.5±3.4*** 6.2±3.2*** <0.001
Cost in euros/year of medications treating for:
Diabetes 212.6±35.8 188.8±36.2* 196.0±52.9 143.1±43.7* 135.1±43.9* 0.014
Blood pressure 270.4±37.7 263.1±37.4 242.7±39.7 205.2±37.2*† 215.0±41.1 0.004
Lipid-lowering 146.4±36.0 146.4±36.0 130.8±36.4 145.6±38.0 122.7±37.0 0.063
Other 677.3±282.3 677.3±282.3 671.5±282.7 685.4±282.5 613.8±270.6 0.069
Significant p Values are written in bold.
Variables written in italic did not follow a Gaussian distribution.
***: p<0.001 versus D0; **: p<0.01 versus D0; *: p<0.05 versus D0.
†††: p<0.001 versus D20; ††: p<0.01 versus D20; †: p<0.05 versus D20 (D0 excluded).
‡‡‡: p<0.001 versus M3; ‡‡: p<0.01 versus M3; ‡: p<0.05 versus M3 (D0 and D20 excluded).
§§§: p<0.001 versus M6; §§: p<0.01 versus M6; §: p<0.05 versus M6 (D0, D20 and M3 excluded).
IL-6, interleukin 6; NT-proBNP, N-terminal pro-brain natriuretic peptide; (TNF)-α, tumor necrosis Factor -α; VEGF, vascular endothelial growth factor.
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who completed the programme and the two participants
who withdrew. At 1 year, decreases of 22.0±0.7% for
glucose, 9.0±0.1% for HbA1c, and 1.0±10.1% for systolic
and 2.0±0.2% for diastolic blood pressure were observed.
Results from anthropometric data showed a decrease of
3.8±1.4% for weight, 7.0±0.1% for waist circumference
and 150.0±0.1% for central fat. Blood lipid proﬁle,
inﬂammation and ﬁtness test followed similar improve-
ments (table 2). The mean compliance scores for diet
and exercise during the at-home follow-up signiﬁcantly
decreased over time, from 56.1±28.2% between D20 and
M3, 48.5±27.3% between M3 and M6 to 37.5±22.1%
between M6 and M12 (p<0.001 for the global
tendency).
Primary outcomes: medications
The 29 patients were followed by 29 different general
practitioners. General practitioners continued their
usual practice for T2D management and cardiovascular
risks. They were not in contact with investigators. Results
of basic blood biology (glycaemia, lipid proﬁle) were
given to participants. Participants were never advised to
see their general practitioner.
At D0, patients consumed 7.56±3.08 tablets/day, that
is, 2758±1124 tablets/year, at a mean routine medication
cost/patient/year of €1352.6±1764.8 (ﬁgure 2). At
1 year, 14 patients out of 26 (54%) ceased or decreased
their medications, whereas only 5 (19%) increased or
introduced new drugs (χ2=6.3, p=0.02). Similarly, 19
medications were ceased or decreased out of 140 (14%)
whereas only 8 (6%) medications were increased or
introduced (χ2=5.0, p=0.02) (table 1). The number of
routine pills signiﬁcantly decreased at each measure-
ment time during the 1-year follow-up. The number of
pills per day decreased by 1.3±0.3 at 12 months
(p<0.001) (ﬁgure 2). For the total cost of routine medi-
cation, the beneﬁt was only signiﬁcant until 3 months
(ﬁgure 2). Although not signiﬁcant (p=0.135) for the
total cost, the decrease in total cost could be estimated
around €110/patient/year at the end of the interven-
tion. The global tendency over the whole 1-year inter-
vention programme was a signiﬁcant decrease of around
€60 in cost of medications treating for T2D (p=0.014),
and a signiﬁcant decrease of €50 in cost of medications
treating for high blood pressure (p=0.004) (ﬁgure 3).
The global tendency was close to signiﬁcance for the
€20 decrease in cost of lipid-lowering drugs (p=0.063)
and for the €60 decrease in cost of other medications
(p=0.069) (ﬁgure 3).
Multivariable analyses
Changes over time in routine medication costs and the
impact of covariates on these changes were separately
modelled using a multivariable GEE modelling that also
accounted for variation in the correlation between the
repeated measurements (ﬁgure 4). In the multivariable
model, we controlled for weight, central fat, blood pres-
sure, lipid proﬁle, glucose metabolism, inﬂammation
and ﬁtness test results. Glycaemia and HbA1c were the
only parameters independently associated with the cost
of routine medication. The regression coefﬁcients on
the cost of routine medication were 0.507 (95% CI 0.056
to 0.959, p=0.027) for HbA1c and 0.156 (95% CI −0.010
to 0.322, p=0.06) for blood glucose levels. Finally, higher
glycaemic control was associated with lower routine
medication costs (ﬁgure 4). Using GLMM, the number
of diabetes participants with high levels of HbA1c
doubled in the high (last quartile) part of routine cost
Figure 2 Number of routine pills per day (mean±SE) and annual cost of all medications (scattergram). +, mean; −, median;
*p<0.05; **p<0.01; ***p<0.001.
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medication: 66% of T2D patients with an HbA1c >6.5%
versus 33% with an HbA1c <6.5% (p=0.037). However,
we did not ﬁnd associations between routine medication
cost and clinical parameters (age, sex, weight, central
fat, blood pressure, blood lipids, inﬂammation or ﬁtness
test).
DISCUSSION
Principal findings
The major ﬁnding showed that the intervention
decreased the number of medications taken by T2D
patients, which represented a reduction around €110
per participant in the annual cost of medication. The
Figure 3 Annual cost of medications for type 2 diabetes, high blood pressure, dyslipidemia and other medications
(scattergrams). +, mean; −, median; *p<0.05; **p<0.01; ***p<0.001.
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independent factor explaining decreased medication
was better glycaemic control: the regression coefﬁ-
cients on the cost of routine medication were 0.507
(95% CI 0.056 to 0.959, p=0.027) for HbA1c and
0.156 (95% CI −0.010 to 0.322, p=0.066) for blood
glucose levels.
Impact of a lifestyle management programme on T2D
medication cost
A simulation model accounting for all costs to the US
healthcare system suggested that within 25 years, lifestyle
intervention programmes would prevent or delay about
885 000 cases of T2D, representing savings of $5.7
billion nationwide.16 Despite the limitations of the
current study precluding generalisability, the interven-
tion decreased the annual cost by €110 per participant.
Taking into account the global pandemic of T2D,17 18
lifestyle intervention would represent non-negligible
ﬁscal savings. A previous study showed markedly
decreased costs to the annual cost of individuals who
had a more severe T2D diagnosis (HbA1c 8%, with com-
plications) when they were exposed to a ‘realistic’ train-
ing protocol.19 We demonstrated that we could generate
a similar magnitude of cost reduction with healthier
T2D participants (HbA1c at 7%, without complications).
Diabetes prevention programmes may achieve even
greater health and economic gains if directed at
younger people.16 Our study was restricted to 50–
70 years old participants and therefore a larger study on
younger T2D patients should be implemented. As previ-
ously suggested,20 the beneﬁts associated with self-
management education and lifestyle modiﬁcation for
people with T2D are positive in terms of health beneﬁts,
and outweigh the costs associated with the intervention.
In our study, the amount reimbursed from the French
national healthcare insurance for the cost of the residen-
tial programme seemed to be approximately equivalent
to the savings in annual routine medication costs.
Impact of glycaemia on health and cost
The improvement in glycaemic control following our resi-
dential programme aligns with the ﬁndings from a recent
meta-analysis demonstrating impacts of physical activity
recommendations associated with an appropriate diet.21
We conﬁrmed the mean HbA1c decrease of 0.6% previ-
ously demonstrated in a meta-analysis including mainly
studies with a 8-week follow-up.22 However, beneﬁts were
still signiﬁcant at 1 year. Improved glycaemic control was
shown to decrease routine medications.3 6 7 18 Such life-
style interventions aiming to control for glycaemic metab-
olism must involve broad resources. To establish
partnerships with health-related institutions is a major
key issue for lifestyle behavioural changes and its long-
term inclusion in the daily lives of individuals with T2D.
It is important to promote collaborations between health
professionals and institutions to raise awareness, train
organisers and discuss management objectives.23
Although a cost-sparing effect of exercise in T2D has
been previously studied,19 the current study was needed
because the treatment of diabetes has been markedly
modiﬁed with the removal of glitazones24 and the
appearance of dipeptidyl peptidase-4 (DPP4) inhibitors
and glucagon-like peptide-1 (GLP1) agonists,25 generat-
ing higher medications costs than were likely to be
incurred at the time of the previous study.26 Few partici-
pants in our study were being administered new drugs
and their costs were not modiﬁed. However, despite lim-
itations precluding generalisability, our intensive exercise
protocol showed signiﬁcant long-term health beneﬁts
and cost reduction in healthier T2D than previously
Figure 4 Relationships between cost of routine medication and clinical and biological parameters (generalised estimating
equations multivariable analyses). *With blood glucose levels: 0.156 (−0.010–0.322), p=0.066; other results were similar.
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reported.19 We demonstrated for the ﬁrst time that those
cost improvements were mediated by a better glycaemic
control and not by weight loss or other variables.27 28
Strengths and limitations
The strengths of our study are a run-in design with
community-based long-term intervention; we evaluated
the cost of global routine medication in T2D patients;
and we used an appropriate model to assess the inde-
pendent associations of routine medication costs with
only glycaemic control, taking into account variations of
correlations over time. Innovation also lies in training
volumes (15–20 hours/week) that have seldom been
investigated in obesity intervention over 12 months.
The main limitations of this study are a small sample
size of T2D patients and the absence of a randomised
controlled trial design. A group without physical activity
could have provided opportunities to distinguish the
effects of physical activity from the diet. Owing to the
lack of a control group without intervention, we cannot
assess the inﬂuence of putative side effects of drugs on
cessation or dose decrease of medication. However,
those long-term medication were initiated several years
before our study and most often side effects appear at
the introduction of a medication. Moreover, a physician
from our team had a private interview with all patients
at each measurement time to assess the rationale for any
changes in medications. The causes of decreased doses
of medication treating for diabetes were decreases in
HbA1c and some hypoglycaemia (even if not common
with biguanides; the reason why general practitioners
did not change sulfamides doses is unknown); the cause
for decreased doses of medication prescribed for high
blood pressure diabetes was lower blood pressure. We
did not repeat the maximal exercise tolerance test due
to limited time available for participants during
follow-up. However, the 6 min walk test is an accurate
tool versus maximal oxygen uptake in evaluating endur-
ance performance.29 Although we previously demon-
strated a link between compliance to new lifestyle and
health beneﬁts,30 31 the limited sample size of this study
did not retrieve signiﬁcant relationships. Implementing
our intervention into routine healthcare is costly and
our high volume training protocol (15 hours/week) may
prove difﬁcult to comply with in usual practice. The
implementation of this programme would require sub-
stantial ﬁnancial resources; thus, budgetary constraints
could limit the number of people to whom the lifestyle
intervention could be delivered. Moreover, there seems
to be a tendency to steady state and even a mild reversal
of the global effect at 12 months for some variables,
which could be due to a relative decrease in training
volume reported during the follow-up. Difﬁculty in
maintaining the long-term high volume of training
could be one of the pitfalls of such interventions and
may require a revised prescription of exercise at regular
intervals. The question of the modalities of exercise
training during follow-up for a better compliance and
health beneﬁts should generate new hypotheses.
Eventually, despite beneﬁts in terms of cost of routine
medications for patients and French national healthcare
insurance, the cost-effectiveness impact of our interven-
tion on overall medical cost in terms of complications of
T2D, number of hospitalisations and length of hospital
stays would have required a prolonged follow-up over
several years in a large sample size. Even if such studies
are speciﬁc of a national health system, our results may
be largely generalisable to other situations in various
countries.
CONCLUSION
In a small sample of T2D patients, reducing the long-
term cost of global routine medication and number of
pills could be effective following a 3-week lifestyle resi-
dential combining high exercise volume, restrictive diet
and education. The only factor correlated with this
decreased medication cost was the glycaemic control in
the absence of weight change. Implementing such a pro-
gramme could be an efﬁcient use of healthcare
resource. To maintain this lifestyle education in long
term may need the support of health related institutions
specialised in T2D patients’ management.
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